Artimplant AB's Interim Report January 1- March 31, 2004

STOCKHOLM, Sweden, April 27, 2004 (PRIMEZONE) -- Artimplant AB:

Several New Regulatory Approvals and a Strong Financial Position

-- Artimplant's net sales for the period reached SEK 1.0 million (SEK 1.0 million)

-- Losses after tax was SEK 6.6 million (SEK 5.9 million), the loss per share was SEK 0.17 (SEK -0.30)

-- Three new CE-certificates were granted, which cleared the way for product sales in EU

-- Good results from the study of accelerated rehab with Artelon(R) Augmentation Device ACL, and in thumb joint surgery with UCL Augmentation Device

-- Extended test sales of Artelon(R) Augmentation Device ACL in the United Kingdom

-- The directed share issue, based on the over subscription of the December rights issue, yielded over SEK 14 millions

This information was brought to you by Waymaker http://www.waymaker.net

The full report is available for download:

Tags